Biopsychosocial Response to the COVID-19 Lockdown in People with Major Depressive Disorder and Multiple Sclerosis.

Autor: Siddi S; Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM (Madrid 28029), Universitat de Barcelona, 08007 Barcelona, Spain., Giné-Vázquez I; Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM (Madrid 28029), Universitat de Barcelona, 08007 Barcelona, Spain., Bailon R; Aragón Institute of Engineering Research (I3A), University of Zaragoza, 50001 Zaragoza, Spain.; Centros de Investigación Biomédica en Red en el Área de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain., Matcham F; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK.; School of Psychology, University of Sussex, Falmer BN1 9QH, UK., Lamers F; Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.; Mental Health Program, Amsterdam Public Health Research Institute, 1081 BT Amsterdam, The Netherlands., Kontaxis S; Aragón Institute of Engineering Research (I3A), University of Zaragoza, 50001 Zaragoza, Spain.; Centros de Investigación Biomédica en Red en el Área de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain., Laporta E; Centros de Investigación Biomédica en Red en el Área de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain., Garcia E; Centros de Investigación Biomédica en Red en el Área de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain.; Microelectrónica y Sistemas Electrónicos, Universidad Autónoma de Barcelona, 08193 Bellaterra, Spain., Arranz B; Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM (Madrid 28029), Universitat de Barcelona, 08007 Barcelona, Spain., Dalla Costa G; Faculty of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy., Guerrero AI; Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Zabalza A; Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Buron MD; Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark., Comi G; Faculty of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy.; Casa Cura Policlinico, 20144 Milan, Italy., Leocani L; Faculty of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy.; Experimental Neurophysiology Unit, Institute of Experimental Neurology-INSPE, Scientific Institute San Raffaele, 20132 Milan, Italy., Annas P; H. Lundbeck A/S, 2500 Valby, Denmark., Hotopf M; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., Penninx BWJH; Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.; Mental Health Program, Amsterdam Public Health Research Institute, 1081 BT Amsterdam, The Netherlands., Magyari M; Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark., Sørensen PS; Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark., Montalban X; Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Lavelle G; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., Ivan A; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., Oetzmann C; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., White KM; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., Difrancesco S; Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands., Locatelli P; Department of Engineering and Applied Science, University of Bergamo, 24129 Bergamo, Italy., Mohr DC; Center for Behavioral Intervention Technologies, Department of Preventative Medicine, Northwestern University, Chicago, IL 60611, USA., Aguiló J; Centros de Investigación Biomédica en Red en el Área de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain.; Microelectrónica y Sistemas Electrónicos, Universidad Autónoma de Barcelona, 08193 Bellaterra, Spain., Narayan V; Research and Development Information Technology, Janssen Research & Development, LLC, Titusville, NJ 08560, USA., Folarin A; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., Dobson RJB; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., Dineley J; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., Leightley D; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., Cummins N; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., Vairavan S; Research and Development Information Technology, Janssen Research & Development, LLC, Titusville, NJ 08560, USA., Ranjan Y; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., Rashid Z; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., Rintala A; Department for Neurosciences, Center for Contextual Psychiatry, Katholieke Universiteit Leuven, 7001 Leuven, Belgium.; Faculty of Social Services and Health Care, LAB University of Applied Sciences, 15210 Lahti, Finland., Girolamo G; IRCCS Instituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy., Preti A; Dipartimento di Neuroscienze, Università degli Studi di Torino, 10126 Torino, Italy., Simblett S; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., Wykes T; Institute of Psychiatry, King's College London, Psychology and Neuroscience, London SE5 8AF, UK., Pab Members, Myin-Germeys I; Department for Neurosciences, Center for Contextual Psychiatry, Katholieke Universiteit Leuven, 7001 Leuven, Belgium., Haro JM; Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM (Madrid 28029), Universitat de Barcelona, 08007 Barcelona, Spain., On Behalf Of The Radar-Cns Consortium
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2022 Dec 01; Vol. 11 (23). Date of Electronic Publication: 2022 Dec 01.
DOI: 10.3390/jcm11237163
Abstrakt: Background: Changes in lifestyle, finances and work status during COVID-19 lockdowns may have led to biopsychosocial changes in people with pre-existing vulnerabilities such as Major Depressive Disorders (MDDs) and Multiple Sclerosis (MS).
Methods: Data were collected as a part of the RADAR-CNS (Remote Assessment of Disease and Relapse-Central Nervous System) program. We analyzed the following data from long-term participants in a decentralized multinational study: symptoms of depression, heart rate (HR) during the day and night; social activity; sedentary state, steps and physical activity of varying intensity. Linear mixed-effects regression analyses with repeated measures were fitted to assess the changes among three time periods (pre, during and post-lockdown) across the groups, adjusting for depression severity before the pandemic and gender.
Results: Participants with MDDs (N = 255) and MS (N = 214) were included in the analyses. Overall, depressive symptoms remained stable across the three periods in both groups. A lower mean HR and HR variation were observed between pre and during lockdown during the day for MDDs and during the night for MS. HR variation during rest periods also decreased between pre- and post-lockdown in both clinical conditions. We observed a reduction in physical activity for MDDs and MS upon the introduction of lockdowns. The group with MDDs exhibited a net increase in social interaction via social network apps over the three periods.
Conclusions: Behavioral responses to the lockdown measured by social activity, physical activity and HR may reflect changes in stress in people with MDDs and MS. Remote technology monitoring might promptly activate an early warning of physical and social alterations in these stressful situations. Future studies must explore how stress does or does not impact depression severity.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje